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ABSTRACT
Phosphodiesterase-9 (PDE9) inhibitors have been studied as
potential therapeutics for treatment of central nervous system
diseases and diabetes. Here, we report the discovery of a new
category of PDE9 inhibitors by rational design on the basis of the
crystal structures. The best compound, (S)-6-((1-(4-chlorophenyl)
ethyl)amino)-1-cyclopentyl-1,5,6,7-tetrahydro-4H-pyrazolo[3,4-
day]pyrimidin-4-one [(S)-C33], has an IC50 value of 11 nM
against PDE9 and the racemic C33 has bioavailability of 56.5%
in the rat pharmacokinetic model. The crystal structures of PDE9
in the complex with racemic C33, (R)-C33, and (S)-C33 reveal
subtle conformational asymmetry of two M-loops in the PDE9
dimer and different conformations of two C33 enantiomers. The
structures also identified a small hydrophobic pocket that
interacts with the tyrosyl tail of (S)-C33 but not with (R)-C33,
and is thus possibly useful for improvement of selectivity of
PDE9 inhibitors. The asymmetry of the M-loop and the different
interactions of the C33 enantiomers imply the necessity to
consider the whole PDE9 dimer in the design of inhibitors.
Introduction
Phosphodiesterase (PDE) is a superfamily of enzymes
hydrolyzing the second messengers, cGMP and cAMP. For
the critical roles of cAMP and cGMP in physiologic processes,
PDEs have been studied as drug targets for treatment of
various diseases (Conti and Beavo, 2007; Maurice et al., 2014).
The human genome contains 21 genes that are categorized into
11 PDE families and express.100 isoforms (Conti and Beavo,
2007; Maurice et al., 2014). PDE5, PDE6, and PDE9 specifi-
cally recognize cGMP as their substrate, while PDE4, PDE7,
and PDE8 are cAMP-specific. The remaining PDE families are
capable of degrading both substrates. PDE9 inhibitors have
been studied for their potential applications to treat diabetes
(Deninno et al., 2009; Shao et al., 2014) and central nervous
system diseases such as Alzheimer’s disease (Wunder et al.,
2005; van der Staay et al., 2008; Verhoest et al., 2009, 2012;
Hutson et al., 2011; Vardigan et al., 2011; Claffey et al., 2012;
Kleiman et al., 2012; Kroker et al., 2012, 2014; Liddie et al.,
2012; Schwam et al., 2014; Singh and Patra, 2014; Heckman
et al., 2015; Nagy et al., 2015).
On the other hand, since almost all important biomacromo-
lecules such as proteins and nucleic acids exist in chiral forms,
enantiomeric molecular recognition is the most important
biologic process in nature. Similarly, when exogenous com-
pounds such as drugs are introduced into the human body,
chiral discrimination plays a fundamental role in determining
the pharmacokinetic properties and biorecognition of drugs in
physiologic processes (Agranat et al., 2002). The market share
for single-enantiomer drugs increased from 27% (US$74.4
billion) in 1996 to 40%–50% in the pharmaceutical market
today (Shaner et al., 2005; Sekhon, 2013). Recently, legal
regulations have intended to allow only single-enantiomer
drugs to be marketed (Mentel et al., 2009). Despite the
importance of the drug chirality, the impacts of potentially
different bindings of enantiomers on biologic effects have not
been completely illustrated (Londesborough, 1985).
In this paper, we report a novel category of PDE9 inhibitors
that have been discovered by using the rational structure-based
designanddocking on the basis of our early analogs of 28s and 3r
(Meng et al., 2012; Shao et al., 2014). The crystal structures
of PDE9 in the complex with the best compound, (S)-6-((1-(4-
chlorophenyl)ethyl)amino)-1-cyclopentyl-1,5,6,7-tetrahydro-
4H-pyrazolo[3,4-day]pyrimidin-4-one [(S)-C33], and a systematic
comparison among PDE9 structures in the RCSB Protein Data
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Bank (www.rcsb.org/pdb) revealed subtle but significant confor-
mation differences between two M-loops in the PDE9 dimers.
In addition, the crystal structure of PDE9A-C33 identified
a small hydrophobic pocket that interacted with (S)-C33 only,




PDE9A (PDB ID: 4GH6) was used for docking by CDOCKER (Wu
et al., 2003) and LigandFit (Venkatachalam et al., 2003) embedded in
Accelrys Discovery Studio 2.5.5. Hydrogen atoms and charges were
generated by the CHARMM force field and the Momany-Rone partial
charge method. All ionizable residues were set to their protonation
states. Charges of zinc and magnesium ions were assigned to12. The
radius of the docking sphere was set to 10 Å. The default values were
used for the rest of the docking parameters. The PDE9A inhibitor 28s
(Meng et al., 2012) was used as a reference for the docking test. The
reliability of the docking results is also confirmed by a comparison
between the docking poses and the crystal structure of PDE9-(S)-C33
(Supplemental Fig. 1). Fifty conformations of each ligand were
randomly generated, docked, and output for evaluation. The candi-
dates with high scores and reasonable binding patterns were chem-
ically synthesized.
Synthesis
1H NMR and 13C NMR spectra were recorded at room temperature
on a Bruker AVANCE III 400 (Karlsruhe, Germany) instrument with
tetramethylsilane as an internal reference. The abbreviations of s, d, t,
q, p, hept, m, and brs represent singlet, doublet, triplet, quartet,
pentet, heptet, multiplet, and broad singlet, respectively. Optical
rotations were measured using a Bellingham + Stanley ADP 440+
polarimeter (Kent, UK). Liquid chromatography mass spectrometry
(MS) equipment LCMS-2010A (Shimadzu, Japan) was used for mass
analysis. Thin-layer chromatography was performed on precoated
silica gel F-254 plates (0.25mm) (Merck kGaA, Darmstadt, Germany).
Elemental analysis was carried out with a Vario EL cube series
analyzer (Elementar, Germany). The m.p. values were determined on
a WRS-1B (Shanghai Jingke Industrial Co. Ltd., China) digital m.p.
apparatus and were not calibrated. Infrared (IR) spectra were
recorded on a (Nicolet Avatar 330 FT-IR, Thermo Scientific, Waltham,
MA). All starting materials and reagents were purchased from
commercial suppliers and used directly without further purification.
The syntheses of the compounds are outlined in scheme 1.
Compounds P1–P3 were synthesized according to the protocol pre-
viously reported in Shao et al. (2014). The syntheses of the target
compounds are briefly described as follows: i-PrOH (2ml), pyrimidinone
(0.3 mmol), amine (1.0 mmol), and Et3N (1.0 mmol) were added to a
10-ml sealed vial. The reaction mixture was stirred in an oil bath
preheated to 100°C. After pyrimidinone was consumed, as indicated by
thin-layer chromatography, the reaction mixture was cooled to room
temperature and concentrated in vacuo. The residue was purified by
flash column chromatography on silica gel to provide the target
compounds. The following sections describe the targeted compounds.
(6)-1-Isopropyl-6-((1-Phenylethyl)Amino)-1,5-Dihydro-4H-
Pyrazolo[3,4-Day]Pyrimidin-4-One. White solids (83 mg, yield:
93%);m.p. 67–68°C;MS (ESI2):m/z 296 ([M-H]2); 1HNMR (400MHz,
CDCl3) 10.70 (brs, 1H), 7.59 (s, 1H), 7.47–7.42 (m, 2H), 7.35 (t, J5 7.5
Hz, 2H), 7.30–7.26 (m, 1H), 7.20 (d, J5 7.3Hz, 1H), 5.26 (q, J5 7.0Hz,
1H), 4.89–4.79 (m, 1H), 1.66 (d, J 5 6.8 Hz, 3H), 1.51 (d, J 5 6.8 Hz,
3H), and 1.46 (d, J5 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 160.3,
154.0, 152.1, 143.7, 133.9, 128.6, 127.3, 126.1, 99.9, 50.6, 49.0, 22.60,
21.6, and 21.5; and IR (KBr, cm21): 3327, 2977, 1681, 1615, 1553, 1507,
1442, 1259, 1120, 782, and 670. Analysis calculated for
C16H19N5O×0.5H2O: C, 62.73; H, 6.58; and N, 22.86; found: C, 62.90;
H, 6.34; and N, 22.85.
6-(Benzyl(Methyl)amino)-1-Isopropyl-1,5-Dihydro-4H-Pyra-
zolo[3,4-Day]Pyrimidin-4-One. White solids (72 mg, yield: 80%);
m.p. 187–188°C; MS (ESI2), m/z 296 ([M-H]2); 1H NMR [500 MHz,
dimethylsulfoxide (DMSO)-d6] d 10.66 (brs, 1H), 7.75 (s, 1H), 7.36–
7.32 (m, 2H), 7.30–7.25 (m, 3H), 4.82 (s, 2H), 4.74 (hept, J 5 6.7 Hz,
1H), 3.08 (s, 3H), and 1.37 (d, J 5 6.7 Hz, 6H); 13C NMR (126 MHz,
DMSO-d6) d 158.5, 153.3, 152.9, 137.3, 133.5, 128.4, 127.3, 127.1, 99.0,
52.4, 47.8, 35.7, and 21.5; and IR (KBr, cm21): 3120, 3050, 2979, 2934,
1676, 1595, 1544, 1387, 1285, 1113, 1003, 974, 815, 779, 729, and 698.
Analysis calculated for C16H19N5O: C, 64.63; H, 6.44; and N, 23.55;
found: C, 64.59; H, 6.26; and N, 23.43.
(6)-6-((1-(4-Chlorophenyl)Ethyl)Amino)-1-Isopropyl-1,5-
Dihydro-4H-Pyrazolo[3,4-Day]Pyrimidin-4-One. White sol-
ids (69 mg, yield: 69%); m.p. 67–68°C; MS (ESI2): m/z 330 ([M-H]2);
1H NMR (400 MHz, CDCl3) d 10.70 (brs, 1H), 7.65 (s, 1H), 7.34 (d, J5
8.5 Hz, 2H), 7.30–7.26 (m, 2H), 7.14 (d, J5 7.0 Hz, 1H), 5.18 (q, J5 6.9
Hz, 1H), 4.73–4.79 (m, 1H), 1.61 (d, J5 7.0Hz, 3H), 1.48 (d, J5 6.7Hz,
3H), and 1.41 (d, J5 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 160.3,
153.9, 152.0, 142.5, 133.7, 132.9, 128.7, 127.5, 99.9, 50.1, 49.0, 22.7,
21.6, and 21.5; and IR (KBr, cm21): 3321, 2977, 1681, 1615, 1553, 1444,
1259, 1092, 1013, 827, 781, and 680. Analysis calculated for
C16H18ClN5O: C, 57.92; H, 5.47; and N, 21.11; found: C, 58.20; H,
5.64; and N, 20.76.
(6)-1-Cyclopentyl-6-((1-Phenylethyl)Amino)-1,5-Dihydro-
4H-Pyrazolo[3,4-Day]Pyrimidin-4-One. White solids (78 mg,
yield: 80%); m.p. 172–174°C; MS (ESI2): m/z 322 ([M-H]2); 1H NMR
(400 MHz, CDCl3) d 10.70 (brs, 1H), 7.58 (s, 1H), 7.45–7.39 (m, 2H),
7.36–7.31 (m, 2H), 7.29–7.24 (m, 1H), 7.13 (d, J5 7.0 Hz, 1H), 5.25 (q,
J5 6.8 Hz, 1H), 4.96 (p, J5 7.6 Hz, 1H), 2.12–2.05 (m, 2H), 2.05–1.98
(m, 2H), 1.97–1.88 (m, 2H), 1.75–1.67 (m, 2H), and 1.65 (d, J5 6.9 Hz,
3H); 13C NMR (101 MHz, CDCl3) d 160.3, 154.4, 152.1, 143.7, 133.9,
128.6, 127.3, 126.1, 99.9, 57.9, 50.6, 31.9, 31.7, 24.7, 24.7, and 22.6; and
IR (KBr, cm21): 3317, 2960, 2868, 1680, 1615, 1555, 1443, 1258, 1121,
Scheme 1. Synthesis of PDE9 inhibitors (PDE9 I).
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1066, 1012, 782, 698, and 550. Analysis calculated for C18H21N5O×0.1
H2O: C, 66.48; H, 6.57; and N, 21.54; found: C, 66.47; H, 6.44; and
N, 21.20.
6-(Benzyl(Methyl)Amino)-1-Cyclopentyl-1,5-Dihydro-4H-
Pyrazolo[3,4-Day]Pyrimidin-4-One. White solids (45 mg, yield:
46%); m.p. 169–170°C; MS (ESI2): m/z 322 ([M-H]2); 1H NMR (400
MHz, DMSO-d6) d 7.76 (s, 1H), 7.39–7.23 (m, 5H), 4.96–4.86 (m, 1H),
4.82 (s, 2H), 3.08 (s, 3H), 2.03–1.76 (m, 6H), and 1.67–1.56 (m, 2H); 13C
NMR (101 MHz, DMSO-d6) d 158.6, 153.4, 137.4, 133.7, 128.5, 127.4,
127.2, 99.1, 56.8, 52.4, 35.8, 31.6, and 24.3; and IR (KBr, cm21): 3112,
2953, 1865, 1593, 1566, 1546, 1388, 1358, 1293, 1055, 1004, 776, and
705. Analysis calculated for C18H21N5O×0.4H2O: C, 65.39; H, 6.65; and
N, 21.18; found: C, 65.79; H, 6.41; and N, 20.84.
(6)-6-((1-(4-Chlorophenyl)Ethyl)Amino)-1-Cyclopentyl-
1,5,6,7-Tetrahydro-4H-Pyrazolo[3,4-Day]Pyrimidin-4-One.
White solids (49 mg, yield: 46%); m.p. 209–210°C;MS (ESI2):m/z 356
([M-H]2); 1H NMR (400 MHz, CDCl3) d 10.72 (brs, 1H), 7.64 (s, 1H),
7.36–7.32 (m, 2H), 7.30–7.26 (m, 2H), 7.07 (d, J 5 7.1 Hz, 1H), 5.18
(q, J 5 6.9 Hz, 1H), 4.90 (p, J 5 7.5 Hz, 1H), 2.09–2.03 (m, 2H), 2.01–
1.95 (m, 2H), 1.94–1.85 (m, 2H), 1.73–1.65 (m, 2H), and1.61 (d,J57.0Hz,
3H); 13C NMR (100 MHz, CDCl3) d 160.3 154.3, 151.9, 142.5, 133.7,
132.9, 128.7, 127.4, 99.9, 57.9, 50.1, 31.9, 31.7, 24.7, and 22.9; and IR
(KBr, cm21): 3309, 2959, 2869, 1680, 1614, 1552, 1492, 1446, 1259,
1092, 1014, 825, and 780. Analysis calculated for C18H20ClN5O: C,
60.42; H, 5.63; and N, 19.57; found: C, 60.44; H, 5.84; and N, 19.28.
(R)-6-((1-(4-Chlorophenyl)Ethyl)Amino)-1-Cyclopentyl-
1,5,6,7-Tetrahydro-4H-Pyrazolo[3,4-Day]Pyrimidin-4-One [(R)-
C33]. White solids (56 mg, yield: 52%); MS (ESI2):m/z 356 ([M-H]2);
1H NMR (400 MHz, CDCl3) d 10.74 (brs, 1H), 7.66 (s, 1H), 7.38–7.34
(m, 2H), 7.33–7.27 (m, 2H), 7.18 (d, J5 6.9 Hz, 1H), 5.21 (q, J5 6.9 Hz,
1H), 4.94 (p, J5 7.5Hz, 1H), 2.12–1.91 (m, 6H), 1.77–1.68 (m, 2H), and
1.64 (d, J 5 7.0 Hz, 3H); and 13C NMR (100 MHz, CDCl3) d 160.3,
154.3, 151.9, 142.4, 133.7, 132.9, 128.7, 127.4, 99.9, 57.9, 50.1, 32.0,
31.7, 24.8, 24.7, and 22.8. Analysis calculated for C18H20ClN5O: C,
60.42; H, 5.63; and N, 19.57; found: C, 60.18; H, 5.68; and N, 19.39;
½a20D 5 192 (c 5 1 g/L, CHCl3).
(S)-6-((1-(4-Chlorophenyl)Ethyl)Amino)-1-Cyclopentyl-1,5,6,7-
Tetrahydro-4H-Pyrazolo[3,4-Day]Pyrimidin-4-One [(S)-C33].
White solids (52 mg, yield: 49%); MS (ESI2): m/z 356 ([M-H]2); 1H
NMR (400MHz, CDCl3) d 10.71 (s, 1H), 7.66 (s, 1H), 7.40–7.34 (m, 2H),
7.34–7.29 (m, 2H), 7.24 (d, J 5 7.0 Hz, 1H), 5.21 (q, J 5 6.9 Hz, 1H),
4.94 (p, J5 7.5 Hz, 1H), 2.13–1.90 (m, 6H), 1.75–1.67 (m, 2H), and 1.64
(d, J 5 7.0 Hz, 3H); and 13C NMR (100 MHz, CDCl3) d 160.3, 154.3,
151.9, 142.5, 133.7, 132.9, 128.7, 127.4, 99.9, 57.9, 50.0, 32.0, 31.7,
24.8, 24.7, and 22.8. Analysis calculated for C18H20ClN5O: C, 60.42; H,
5.63; and N, 19.57; found: C, 60.54; H, 5.66; and N, 19.71; ½a20D 5 2 93
(c 5 1 g/L, CHCl3).
(6)-6-((1-(4-Chlorophenyl)-2-Methylpropyl)Amino)-1-
Cyclopentyl-1,5,6,7-Tetrahydro-4H-Pyrazolo[3,4-Day]
Pyrimidin-4-One (C40). White solids (79 mg, yield: 68%); m.p.
210–212°C;MS (ESI2):m/z 386 ([M-H]2); 1HNMR (400MHz, DMSO-d6)
d 10.23 (s, 1H), 7.72 (s, 1H), 7.37 (m, 4H), 7.08 (s, 1H), 4.88–4.77
(m, 1H), 4.70–4.65 (m, 1H), 2.07–2.03 (m, 1H), 2.01–1.73 (m, 6H), 1.70–
1.49 (m, 2H), 0.95 (d, J5 6.7 Hz, 3H), and 0.82 (d, J5 6.7 Hz, 3H); 13C
NMR (126 MHz, CDCl3) d 160.3, 154.4, 152.4, 140.6, 133.8, 132.7,
TABLE 1
Statistics on the diffraction data and structure refinement
PDE9-C33 PDE9-(S)-C33 PDE9-(R)-C33
Data collection
Space group P41212 P41212 P41212
Unit cell (a, c, Å) 103.6, 268.7 104.7, 270.3 105.4, 270.1
Resolution (Å) 2.0 2.7 3.1
Total measurements 1,215,951 688,294 161,116
Unique reflections 96,827 42,348 24,552
Completeness (%) 97.2 (91.9)a 100.0 (100.0) 84.9 (85.4)
Average I/s 20.8 (3.5)a 7.2 (5.1) 7.6 (2.0)
Rmerge 0.074 (0.274)a 0.125 (0.668) 0.156 (0.717)
Structure refinement
R-work 0.224 (0.457)a 0.205(0.291) 0.215 (0.301)
R-free 0.247 (0.470)a 0.231 (0.326) 0.244 (0.364)
Resolution (Å) 30.0-2.0 50.0-2.7 50.0-3.1
Reflections 94,640 (5%)b 40,241 (5%) 23,302 (5%)
RMSD for bond length (Å) 0.007 0.008 0.007
RMSD for bond angle (o) 1.1 1.1 1.1
Average B-factor (Å2)
Protein 40.4 (5357)c 41.6 (5337) 62.1 (5357)
Inhibitor 37.9 (50) 37.8 (50) 61.3 (50)
Zn2+ 48.1 (2) 51.7 (2) 71.8 (2)
Mg2+ 31.8 (2) 32.5(2) 50.6 (2)
Water 39.0 (255) 29.1 (12) 42.6 (12)
Ramachandran plot (%)
Favored 93.8 93.0 91.5
Allowed 5.9 6.3 8.3
Generally allowed 0.3 0.7 0.2
Disallowed 0.0 0.0 0.0
aThe numbers in parentheses are for the highest resolution shells of 2.0–2.05, 2.7–2.77, and 3.1–3.17 Å, respectively,
for the PDE9 structures in the complex with racemic C33, (S)-C33, and (R)-C33.
bThe percentage of reflections omitted for calculation of R-free.
cThe number of atoms in the structure refinement.
Fig. 1. Chemical structures of PDE9 inhibitors assessed in this study
(*, chiral carbon).
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TABLE 2
Inhibition of synthetic compounds on PDE9
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128.4, 128.3, 99.8, 60.8, 57.7, 33.8, 32.0, 31.6, 24.7, 24.7, 19.9, and 19.2;
and IR (KBr, cm21): 3344, 2931, 2852, 1689, 1610, 1552, 1506, 1491,
1441, 1265, 1251, 1089, 1051, 1012, 989, 827, 816, 781, 621, 581, and
557. Analysis calculated for C20H24ClN5O×0.15H2O: C, 61.82; H, 6.30;
and N, 18.02; found: C, 62.11; H, 6.12; and N, 17.74.
(6)-1-Isobutyl-6-((1-Phenylethyl)Amino)-1,5-Dihydro-4H-
Pyrazolo[3,4-Day]Pyrimidin-4-One. White solids (52 mg, yield:
54%);m.p. 84–85°C;MS (ESI2):m/z 310 ([M-H]2); 1HNMR (400MHz,
CDCl3) d 10.66 (brs, H), 7.48 (s, H), 7.43–7.39 (m, 2H), 7.36–7.29
(m, 2H), 7.29–7.21 (m, 1H), 7.16 (d, J5 6.9 Hz, 1H), 5.20 (q, J5 6.8 Hz,
1H), 4.00–3.88 (m, 2H), 2.28–2.11 (m, 1H), 1.64 (d,J5 6.9Hz, 3H), 0.88
(d, J 5 6.7 Hz, 3H), and 0.81 (d, J 5 6.7 Hz, 3H); 13C NMR (101 MHz,
CDCl3) d 160.3, 155.1, 152.3, 143.7, 134.1, 128.6, 127.3, 126.2, 99.4,
54.1, 50.7, 28.9, 22.4, 20.0, and 19.9; and IR (KBr, cm21): 3489, 3268,
2962, 1680, 1611, 1566, 1520, 1457, 1277, 1094, 882, 756, 699, 554, and
476. Analysis calculated for C17H21N5O×0.3H2O: C, 64.45; H, 6.87; and
N, 22.11; found: C, 64.71; H, 7.06; and N, 21.86.
6-(Benzyl(Methyl)Amino)-1-Isobutyl-1,5-Dihydro-4H-Pyr-
azolo[3,4-Day]Pyrimidin-4-One. White solids (39 mg, yield:
42%); m.p. 187–188°C; MS (ESI2): m/z 310 ([M-H]2); 1H NMR (400
MHz, DMSO-d6) d 7.78 (s, 1H), 7.37–7.22 (m, 5H), 4.80 (s, 2H), 3.88
(d, J5 7.1 Hz, 2H), 3.08 (s, 3H), 2.16–2.05 (m, 1H), and 0.79 (d, J5 6.7
Hz, 6H); 13C NMR (101 MHz, DMSO-d6) d 159.2, 154.6, 153.9, 138.0,
134.4, 128.9, 127.9, 127.7, 99.0, 53.5, 53.0, 36.3, 29.0, and 20.2; and IR
(KBr, cm21): 3117, 2958, 1692, 1580, 1453, 1387, 1314, 1157, 1056,
1013, 884, 809, 780, 699, 627, 563, and 474. Analysis calculated for
C17H21N5O: C, 65.57; H, 6.80; and N, 22.49; found: C, 65.56; H, 6.76;
and N, 22.30.
(6)-6-((1-(4-Chlorophenyl)Ethyl)Amino)-1-Isobutyl-1,5-Dihy-
dro-4H-Pyrazolo[3,4-day]Pyrimidin-4-One. White solids (61 mg,
yield: 58%);m.p. 88–89°C;MS (ESI2):m/z 344 ([M-H]2); 1HNMR (400
MHz, CDCl3) d 10.79 (brs, 1H), 7.65 (s, 1H), 7.34–7.27 (m, 4H), 6.88
(d, J 5 6.7 Hz, 1H), 5.13 (q, J 5 6.8 Hz, 1H), 3.96–3.85 (m, 2H), 2.21–
2.10 (m, 1H), 1.61 (d, J5 7.0 Hz, 3H), 0.87 (d, J5 6.7 Hz, 3H), and 0.79
(d, J5 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 160.4, 155.0, 152.0,
142.5, 134.0, 132.9, 128.7, 127.4, 99.5, 54.2, 50.3, 28.9, 22.7, 20.0, and
19.8; and IR (KBr, cm21): 3429, 3270, 2964, 2930, 1678, 1608, 1560,
1516, 1458, 1401, 1318, 1270, 1171, 1094, 1014, 824, 780, 589, and 539.
Analysis calculated for C17H20ClN5O×0.9H2O: C, 56.40; H, 6.07; andN,
19.34; found: C, 56.48; H, 6.14; and N, 19.12.
Protein Expression and Purification
The PDE9A2 catalytic domain (residues 181–506) was subcloned to
vector pET15b and purified according to the protocols described by
Huai et al. (2004). Briefly, the pET15-PDE9 plasmid was transferred
into Escherichia coli strain BL21 (Codonplus, Stratagene, Santa
Clara, CA) for overexpression. When the E. coli cell was grown in LB
medium at 37°C to absorption (A600 5 0.7), 0.1 mM isopropyl b-D-
thiogalactopyranoside was added to induce the expression at 15°C
overnight. Recombinant PDE9A2 proteinwas purified by column chro-
matography of Ni-NTA (GE Healthcare, Pittsburgh, PA), Q-sepharose
(GE Healthcare), and Superdex-200 (GE Healthcare). A typical batch
of purification yielded 20–60 mg PDE9A2 from a liter of cell culture.
The PDE9A2 protein had purity .90% as judged by SDS-PAGE.
The catalytic domains of PDE2A3 (222–904), PDE4D2 (86–413),
PDE5A1 (535–860), PDE7A1 (130–482), PDE8A2 (480–820), and
PDE10A2 (448–789) were purified by published protocols (Huai
et al., 2003; Wang et al., 2005, 2006, 2007a, 2008a). PDE1B (10–516)
was expressed and purified using a protocol similar to that for PDE9.
Enzymatic Assay
The enzymatic activities of PDE9A2 and other PDEs were assayed
by using 3H-cGMP or 3H-cAMP as the substrate. The assay buffer was
composed of 50 mM Tris-HCl pH 8.0, 10 mM MgCl2 or 4 mM MnCl2,
1 mM DTT, and 20 nM 3H-cGMP or 3H-cAMP (20,000–30,000
cpm/assay) (GE Healthcare). The reaction was carried out at room tem-
perature for 15 minutes and then terminated by addition of 0.2 M ZnSO4.
The reaction 3H-GMP or 3H-AMP products were precipitated by adding
0.2 N Ba(OH)2, whereas the unreacted
3H-cGMP or 3H-cAMP remained
in the supernatant. Radioactivity in the supernatant was measured in
2.5 ml Ultima Gold liquid scintillation cocktails (Fisher Scientific,
Pittsburgh, PA) by a liquid scintillation counter. The final concentra-
tions of the enzymes used in the assay were 50–200 ng/ml, and they
were hydrolyzed up to 70% of the substrates. A total of 9–12 concen-
trations of inhibitors were used for triplet measurement of the IC50 and
S.D. values that were obtained by nonlinear regression.
Crystallization and Structure Determination
The crystals of the PDE9A2 catalytic domain (181–506) in the
complex with racemic C33 and the (R)- and (S)-enantiomers were
grown by the hanging drop vapor diffusion method. The PDE9A2
(8–10 mg/ml) in a buffer of 50mMNaCl, 20mMTris×HCl, pH 7.5, 1 mM
b-mercaptoethanol, and 1 mM EDTA was mixed with 2 mM racemic
C33 or (R)-C33 and cocrystallized against a well buffer of 1.8–2.0 M
sodium formate at 4°C. The PDE9-(S)-C33 crystals were prepared by
soaking the PDE9/3-isobutyl-1-methylxanthine (IBMX) crystals in the
crystallization buffer plus 2 mM (S)-C33 at 25°C for 1 day. The PDE9-
IBMX crystals were grown by the hanging drop method against a well
buffer of 0.1 M HEPES pH 7.5, 3.0 M sodium formate at 4°C. The
crystallization buffer, plus 20% glycerol, was used as the cryosolvent
to freeze the crystals. X-ray diffraction data were collected on Beam-
line X29 at Brookhaven National Laboratory (Upton, NY) (for racemic
C33) or BM22 of SER-CAT at Advanced Photon Source in Chicago (for
(R)-C33 and (S)-C33), and processed by HKL 2000 (Otwinowski and
Minor, 1997). The structures were solved by molecular replacement,
using the PDE9A2 catalytic domain as the initial model. The resulting
models were rebuilt by the program COOT (Emsley et al., 2010) and
refined by REFMAC (Winn et al., 2003). The statistics of the data
collection and structure refinement are listed in Table 1.
Pharmacokinetics Analysis
Six male Sprague Dawley rats with body weights of 240–275 g were
used for the pharmacokinetic experiments. Compound C33 was dis-
solved in 5%DMSO, 5% solutol, and 90% saline tomake a 5mg/ml stock
for i.v. administration and1mg/ml for oral administration (bymouth). A
final dosage of the 5 mg/kg formulated compound was given in both
administration modes. The blood samples were taken at various time
points over 24 hours. The concentration of the compounds in blood was
analyzed by liquid chromatography–tandem MS (Shimadzu liquid
chromatographic system, and API4000 mass spectrometer, Applied
Biosystems, Ontario, Canada).
Stability in Liver Microsomes
Warfarin and testosterone was purchased from Sigma (St. Louis,
MO) and Acros (Geel, Belgium), respectively. Human and mouse
(CD-1) liver microsomes (0.5 ml) (BD Gentest Corporation, Woburn,
MA) were preincubated with 0.75 mM sample in a buffer of 0.1 M
potassium phosphate pH 7.4, and 2 mM MgCl2 in a 96-well plate at
37°C for 5 minutes. The enzymatic reaction was initiated by adding
3 mM NADPH and terminated by adding 90 ml acetonitrile at time
points of 0, 5, 10, 20, and 30 minutes. Parallel incubations were per-
formed for the positive (testosterone) and negative (warfarin) controls.
The supernatant was injected into liquid chromatography–tandem
MS for analysis.
Results
Structure-Based Design and Enzymatic Activity of
PDE9 Inhibitors. We previously reported a potent PDE9
inhibitor, 3r (Fig. 1), which has an IC50 value of 0.6 nM against
PDE9, but only moderate metabolic stability and 10% bio-
availability (Shao et al., 2014). To improve the in vivo stability,
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we designed a series of analogs of 3r and docked them to the
PDE9 crystal structures for confirmation. Since 3r contains an
amide bond that is often labile to acids and proteinases and
may thus account for its moderate bioavailability, we removed
the amide unit of 3r and also optimized the tail group with
hydrocarbon fragments. Removal of the amide group would be
expected to lead to a loss of the hydrogen bond between the
amide nitrogen of the inhibitor and OH of Tyr424, and thus
somewhat sacrifice the affinity and selectivity because Tyr424
is a unique residue for PDE8 and PDE9 (phenylalanine in
other PDE families). However, if the pyrazolopyrimidinone
and cyclic pentanyl groups that contribute the hydrogen bonds
with the invariant glutamine and hydrophobic stack against
the phenylalanine are retained as the scaffold of pharmaco-
phore, optimization of the remaining moiety may lead to
finding new compounds with nearly reasonable affinity and
selectivity. In addition, since the benzenylamine link is
usually sensitive to P450metabolic enzymes in vivo, we hoped
that introduction of the N-alpha substitutent would protect
oxidation of benzenylamine to benzamide. Thus, we rationally
designed a series of new compounds on the basis of the crystal
structures of the PDEs and performed molecular docking to
confirm the design. Compounds from this rational design and
docking were then chemically synthesized and assayed for
their enzymatic properties. The inhibitions of some represen-
tative compounds on PDE9 are listed in Table 2, among which
racemic C33 shows the best IC50 value of 16 nMagainst PDE9.
Overall, the IC50 values of the listed compounds are not dramat-
ically different, perhaps due to the modified groups targeting
similar protein regions and interacting with similar residues.
Based on the observation that the methyl group on the
chiral carbon is neighboring a small hydrophobic pocket in the
PDE9-r3 crystal structure (Shao et al., 2014), we hoped that
the tail of (R)- or (S)-C33 may interact with the hydrophobic
pocket and further improve the affinity and selectivity.
Therefore, racemic and enantiomeric C33s were chemically
synthesized and their inhibitions on the PDE families were
evaluated (Table 3). The enzymatic assay revealed that
racemic, (S)-C33, and (R)-C33 have IC50 values of 16, 11, and
56 nM, respectively, for inhibition on the PDE9 catalytic
domain, and (S)-C33 has reasonably good selectivity over the
other PDE families (Table 3), indicating its potential for
further pharmacological studies.
Improvement in Bioavailability and Stability in Live
Microsomes. While an IC50 value of 11 nM for (S)-C33 is in
the IC50 range of most drugs, it is significantly worse than
0.6 nM for 3r, and also the enzymatic selectivity of (S)-C33
over other PDE families significantly decreases. However, in
terms of bioavailability and in vivo stability, C33 shows
significant improvement over 3r. The oral administration of
racemic C33 yielded a Cmax value of 373 ng/ml and bioavailabil-
ity of 56.5% (Table 4), in comparison with Cmax values of 16 and
217 ng/ml and bioavailability of 1.3% and 9.8% for 28s (Meng
et al., 2012) and 3r (Shao et al., 2014), respectively. The blood
concentration of C33 in the oral administration mode was
113 ng/ml after 6 hours, which is about 19-fold higher than the
IC50 value of 6 ng/ml, indicating practical usability and the
potential for C33 as a drug lead. In addition, the replacement of
theamidebondwithahydrocarbon fragment inC33yieldsstronger
hydrophobicity than 3r, as shown by a log P value of 3.59 C33
in comparison with a log P value of 1.86 for 3r, implying
a strong ability to penetrate the cell membrane.
In addition, the metabolic stability of C33 in human and
mouse liver microsomes suggests that C33 may have better in
vivo stability than 3r. Apparently, the removal of the amide
group from3r significantly improved the stability, as shown by
the T1/2 values of 51 and 12 minutes for racemic C33 and 3r,
respectively, in the human liver microsome, and of 33 and 22
minutes, respectively, in the mouse liver microsome (Table 5).
In the enantiomeric forms of C33, (S)-C33 is apparently more
stable than (R)-C33, as shown by the T1/2 values of 105 and 54
minutes in human and mouse microsomes for (S)-C33, in
comparison with 44 and 22 minutes for (R)-C33. The expla-
nation is not clear, but may be related to their different
conformations and interactions.
On the other hand, we replaced the methyl group of C33
with an isopropanyl group to seek a spatial obstacle for
protection of the C–N bond, and thus lead to the design of
C40 (Fig. 1). Indeed, the stability of C40 was significantly
improved, as shown by theT1/2 values of 62 and 291minutes in
TABLE 4
Pharmacokinetics profile of PDE9 inhibitor C33
Dosing Route T1/2 Tmax Cmax AUC0-t AUC0-inf MRTinf Vz CLz F
hour hour ng/ml ng/h/ml ng/h/ml hour l/kg l/h/kg %
By mouth 1.5 6 0.2 2.0 6 0.0 372 6 6 1600 6 300 1700 6 300 3.5 6 0.3 NA NA 56.5
i.v. 1.4 6 0.1 0.02 6 0.00 5300 6 900 3000 6 200 3100 6 200 1.6 6 0.2 3.2 6 0.1 1.6 6 0.1
AUC, area under the curve; Cl, clearance; MRT, mean residence time; NA, not applicable.
TABLE 3
Affinity of C33 with PDE families
The numbers in parentheses are the fold of selectivity of inhibitors against PDE9 over other PDEs (IC50, nM).
PDE (S)-C33 C33 (R)-C33 3ra
PDE9A (181–506) 11 6 4 16 6 4 58 6 2 0.60 6 0.02
PDE1B2 (10–487) 554 6 64 (46) 152 6 15 (9) 80 6 4 (1.4) 473 6 14 (800)
PDE2A3 (222–904) 2.4 6 0.5 x 103 (200) 437 6 77 (27) 479 6 79 (8) 13 6 0.2  103 (22,000)
PDE4D2 (86–413) 1.3 6 0.1 x 103 (108) 1.8 6 0.2  103 (110) 3.2 6 0.6  103 (56) 21 6 0.7  103 (35,000)
PDE5A1 (535–860) 366 6 38 (31) 197 6 36 (12) 787 6 38 (14) 91 6 23 (151)
PDE7A1 (130–482) 2.5 6 0.4  103 (208) 1.7 6 0.1  103 (104) 1.3 6 0.1  103 (23) 1.8 6 0.7  103 (3000)
PDE8A1 (480–820) 1.0 6 0.2  103 (83) 1.6 6 0.2  103 (98) 4.4 6 0.4  103 (76) .100,000
PDE10A2 (448–789) 2.3 6 0.3  103 (192) 1.2 6 0.1  103 (73) 774 6 11 (13) 6.9 6 0.1  103 (11,000)
aThe data are cited from Shao et al. (2014).
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the human and mouse liver microsomes, respectively
(Table 5), although the IC50 value of C40 against PDE9 was
increased to 73.5 nM.
Asymmetry of PDE9 Dimers. The crystallographic
asymmetric units of PDE9 in complex with racemic or
enantiomeric C33 contain twomolecules of the PDE9 catalytic
domain (Fig. 2). Superposition of subunit A over B in the
PDE9-C33 dimer yielded a root-mean-square deviation
(RMSD) of 0.62 Å for the Ca atoms of the whole domain
(residues 185–506). A systematic superposition of subunit A
over B of the other PDE9 structures in the RCSB Protein Data
Bank resulted in RMSDs in a range of 0.55 and 0.78 Å for the
Ca atoms of residues 185–506. These small RMSDs indicate
an overall similarity between the two subunits of the PDE9
dimers. On the other hand, superposition of PDE9-C33 over
the other PDE9 structures yielded RMSDs of 0.27–0.49 and
0.22–0.42 Å for the comparisons of A versus A and B versus B,
respectively. Similar RMSDs were obtained from the cross-
superposition among other PDE9 structures. Since superpo-
sition between structures reported from different laboratories
often produces higher RMSDs than comparison between
subunits within the same structure, the consistently and
significantly larger RMSDs for A versus B in the same dimers
than for A versus A or B versus B between different structures
suggest asymmetry of the PDE9 dimers.
When the N- and C-terminal residues were excluded, the
superposition between residues 192–486 of the PDE9-C33
dimer yielded a RMSD of 0.17 Å for the Ca atoms, suggesting
flexibility of the N- and C-termini. A careful examination of
the superposition revealed RMSDs of 0.25–0.62 Å for residues
432–440 (the M-loop), which are 1.5- to 4-fold of the overall
average of 0.17 Å for residues 192–486, suggesting significant
conformational differences between two M-loops in the PDE9
dimer. A systematic comparison between subunits A and B of
the PDE9 structures in the Protein Data Bank reveals the
average difference between the Ca atoms of the M-loop in the
dimer is about twice the overall average of the PDE9 catalytic
domain (Table 6), thus confirming the asymmetry of the
M-loop. While the N- and C-termini have the largest RMSD
differences, their biologic relevance is unclear because termi-
nal flexibility is often due to lack of lattice packing in many
crystal structures. However, the difference between the M-
loops of the PDE9 dimers is statistically significant and
appears to be biologically relevant.
The asymmetry of the PDE9 dimer was first observed in the
crystal structure of the PDE9 catalytic domain in the complex
Fig. 2. Ribbon diagram of PDE9-C33. (A) The
PDE9A dimer observed in all PDE9 structures.
Inhibitor C33 is shown as yellow sticks. (B) Super-
position of subunit A (cyan, residues 185–506) over
subunit B (green).
TABLE 5
Metabolic stability of PDE9 inhibitors in human liver microsomes
Compound k T1/2 CLint CLapp CLh Eh
minute ml/min/mg ml/min/mg ml/min/mg %
Testosterone 0.035 20.0 0.069 66.9 15.4 78.0
0.165 4.2 0.329 1296 84.2 93.5
Warfarin 20.001 Stable Stable Stable Stable
20.003 Stable Stable Stable Stable
(S)-C33 0.007 105 0.013 12.7 7.8 38.9
0.013 53.5 0.026 102 47.8 53.1
(R)-C33 0.016 44.0 0.032 30.4 12.1 60.3
0.034 20.2 0.069 270 67.5 75.0
Racemic C33 0.013 51.4 0.027 26.0 11.3 56.5
0.022 31.3 0.044 174 59.4 66.0
C40 0.011 62.2 0.022 21.5 10.4 51.8
0.002 291 0.008 19 15.5 17.2
3ra 0.058 11.9 0.116 112 17.0 84.8
0.031 22.3 0.062 244 65.8 73.1
aThe data are cited from Shao et al. (2014). Cl, clearance.
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with the IBMX inhibitor, in which two IBMX molecules bind
the active sites of the PDE9 dimer with different orientations
(Huai et al., 2004). Later, it was shown that the substrate
cGMP or product GMP easily replaced IBMX in subunit A of
the PDE9-IBMX dimer in the soaking experiments, but not
IBMX in subunit B (Liu et al., 2008). Finally, the asymmetry
was reported for the binding of inhibitor BAY73-6691 to the
Q453Emutant (Hou et al., 2011). The subtle conformational
asymmetry of the M-loop, which is revealed by this study,
may respond to the asymmetric binding/replacement of the
inhibitors.
Different Conformations of Bound C33 Enantiomers.
In the PDE9 structure in the complex with racemic C33, the
electron density in the maps of (2Fo 2 Fc) and (Fo 2 Fc)
revealed binding of the (S)-C33 enantiomer to subunits A and
(R)-C33 to subunit B of the PDE9 dimer (Fig. 3). In the
structures of PDE9 in the complex with enantiomerically pure
(S)-C33 or (R)-C33, the maps showed unique conformations of
(S)-C33 and (R)-C33 bound to both subunits A and B of their
PDE9 dimers. These conformations are identical to that of the
(S)- or (R)-enantiomer, respectively, in the racemic C33-PDE9
complex.
The pyrazolopyrimidinone and cyclic pentanyl rings of C33
in all three structures had the same conformation and were
well superimposable. The pyrazolopyrimidinone rings of C33
formed two hydrogen bonds with invariant Gln453 and
aromatic p-stack against Phe456, in addition to the hydro-
phobic interactions with Leu420 and Ala452. The nitrogen
linked to pyrazolopyrimidinone formed a hydrogen bond with
the carbonyl oxygen of Ala452. The cyclic pentanyl rings of
racemic or enantiomeric C33 occupied the same location near
the metal binding pocket and contacted Met365 and Tyr424.
However, the chlorophenyl tails of (S)-C33 and (R)-C33
oriented to different directions and defined the different
bound conformations of the two enantiomers in the PDE9
dimers (Fig. 3). The chlorophenyl tail of (S)-C33 interacted
with a small hydrophobic pocket, which we tentatively name
the M-pocket (see Discussion), and contacted residues of
Leu420, Leu421, Tyr424, Phe441, Met442, Ala452, and
Phe456. In comparison, the chlorophenyl tail of (R)-C33
pointed out the molecular surface and contacted residues of
Leu420, Tyr424, Phe441, Ala452, and Phe456 (Fig. 3C).
Apparently, the (S)-C33 tail makes more van der Waals
interactions with PDE9 than with (R)-C33, thus explaining
the slightly better binding affinity.
Since the link between chiral carbon and nitrogen (Fig. 1) is
a single bond, free rotation of the bond might produce an
orientation of the (R)-C33 tail in a similar conformation as
(S)-C33 when interacting with the M-pocket. However, the
crystal structure revealed that the chlorobenzyl tail of (R)-C33
oriented to the molecular surface of the PDE9 dimer, instead
of interacting with the M-pocket. The different conformations
and interactions of the tails of the (S)- and (R)-C33 enan-
tiomers might be impacted by the subtle asymmetry of the
M-pocket in the PDE9 dimer. Therefore, the structural in-
formation suggests that both subunits of the PDE9 dimer need
to be considered for design of PDE9 inhibitors.
Discussion
An important Subpocket for Selectivity of PDE
Inhibitors. The early studies on the crystal structures of
PDE9 in the complex with BAY73-6691 (Wang et al., 2010)
and 28s (Meng et al., 2012) showed a small pocket neighboring
the inhibitor binding site. This study revealed that the
chlorophenyl tail of inhibitor (S)-C33 interacts with the small
subpocket that is composed of a portion of helicesH14 andH15
and the M-loop, which we thus tentatively named the
M-pocket (Fig. 4). Helices H14 (Leu420, Leu421, and Phe425)
and H15 contribute two walls of the pocket, while Val447 and
the backbone of the M-loop form the bottom of the pocket. This
small pocket is gated by Ala452 of H15 and Phe441 of the
Fig. 3. Binding of C33 to PDE9A. (A) Surface presentation on binding of (R)-C33 (orange sticks) and (S)-C33 (yellow) to PDE9 dimers. (R)-C33 and
(S)-C33 showed unique conformation in the PDE9 dimer structures, but in the PDE9 dimer in the complex with racemic C33, (R)-C33 binds subunit B and
(S)-C33 binds subunit A. The gray and cyan sticks represent the key residues involved in binding. Dotted lines represent hydrogen bonds. (B) Ribbon
model for (S)-C33 binding to the PDE9 dimer. The red mesh is the electron density in the difference (Fo 2 Fc) map that was calculated from the structure
with omission of (S)-C33 and contoured at 3s. (C) Binding of (R)-C33 to subunit B of the PDE9 dimer.
TABLE 6
The average difference between the Ca atoms of subunits A and B of the PDE9 dimers (Å)
C33 4QGE (3r) 4GH6 (28s) 3JSI 3JSW 4G2J 4G2L 3K3E 3QI3 2HD1 3DYN (cGMP) 3DY8 (GMP)
Residues 181-506 0.32 0.33 0.36 0.32 0.35 0.33 0.31 0.41 0.43 0.39 0.31 0.30
M-loop (S433-K446) 0.59 0.65 0.58 0.48 0.74 0.74 0.67 1.11 1.34 0.80 0.92 0.70
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M-loop and occupies a similar location as the P-pocket in
parasite PDEs. Sequence alignment reveals that the gating
residues vary significantly across PDE families (Fig. 4C), thus
making the pocket inaccessible in many human PDEs (Wang
et al., 2007b, 2012).
In addition, the M-loop shows significant differences in
sequence and conformations (Fig. 4) and is disordered in some
PDE families. Therefore, we believe that the M-pocket may
serve as a selectivity determinant in inhibitor binding, and is
useful in improvement of inhibitor affinity and selectivity. For
example, the M-pocket in PDE5, which is composed of Val782,
Ala783, Phe786, Phe787, and Ile813 (Fig. 5A), is slightly
deeper than that of PDE9. However, two large gating residues
of Leu804 and Met816 would allow a small group to penetrate
into the pocket, such as an ethoxyl fragment in the PDE5-
sildenafil structure (Wang et al., 2008b). This might explain
why (S)-C33 has better selectivity than (R)-C33 against PDE5
(Table 2). The M-pocket in the PDE8A1 structure, which is
made up of residues Ser745, Tyr748, Phe749, Phe767, and
Cys772, is much shallower and smaller than that of PDE9 and
might not well accommodate the C33 inhibitors (Fig. 5B), thus
explaining the poor binding of C33 to PDE8. In the PDE1
structure, the M-loop has good conservation of amino acids, as
shown by the correspondence of Leu388, Met389, and Phe392
of PDE1B to Leu420, Leu421, and Y424 of PDE9, respectively.
Since part of the M-pocket is disordered in PDE1, it might
reasonably predict poor selectivity of PDE9 inhibitors against
PDE1, as observed in the PDE9 structure (Wunder et al., 2005).
Fig. 5. The M-pockets in other PDE
families. (A) Surface presentation of the
M-pocket of PDE5. (B) Surface presenta-
tion of the M-pocket of PDE8A. IBMX is
a nonselective inhibitor ofPDEs. (C) Ribbon
presentation of the superposition of PDE9
(green) over PDE1B (cyan). The M-loop of
PDE1B is partially disordered. The corre-
sponding residues between PDE9A2 and
PDE1B areM365/M336, N405/H373, L420/
L388, L421/M389, Y424/F392, Q453/Q421,
and F456/F424.
Fig. 4. TheM-pocket for inhibitor binding. (A)
Surface model of the M-pocket of PDE9. (B)
Superposition of PDE9 (green ribbons) over
PDE5 (pale) and PDE8A (salmon). Dotted lines
represent hydrogen bonds. (C) Sequence align-
ment for region around the M-pocket of PDEs.
The green color highlights helices in the crystal
structures. The two residues in the red color
gate the pocket.
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